Johan Frostegard
Overview
Explore the profile of Johan Frostegard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
2728
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frostegard J, Akesson A, Helte E, Soderlund F, Su J, Hua X, et al.
JACC Adv
. 2025 Jan;
3(11):101298.
PMID: 39741640
Background: Antibodies against phosphorylcholine (anti-PC) have been reported as associated with protection against atherosclerosis, cardiovascular disease (CVD), and other chronic inflammatory diseases. Underlying potential mechanisms have been demonstrated and include...
2.
Carrera-Bastos P, Fontes-Villalba M, Ahren B, Lindblad U, Rastam L, Frostegard J, et al.
Am J Hum Biol
. 2024 Jul;
36(10):e24134.
PMID: 38989782
Objectives: Experimental and small human studies have indicated that high total adiponectin levels have beneficial cardiometabolic effects. In contrast, however, high total adiponectin levels are also associated with higher all-cause...
3.
Frostegard J
Rheumatology (Oxford)
. 2024 May;
63(10):2613-2614.
PMID: 38775457
No abstract available.
4.
Samal S, Leander K, Vikstrom M, Griesbaum L, de Faire U, Frostegard J
Sci Rep
. 2023 Sep;
13(1):15011.
PMID: 37697019
Malondialdehyde (MDA) is generated in oxidized LDL. It forms covalent protein adducts, and is recognized by antibodies (anti-MDA). We previously studied IgM anti-MDA, and here we focus on IgG, IgG1...
5.
6.
Frostegard J
Metabolites
. 2023 Jun;
13(6).
PMID: 37367878
Atherosclerosis and its main consequence, cardiovascular disease (CVD) are nowadays regarded as chronic inflammatory disease conditions, and CVD is the main cause of death in the world. Other examples of...
7.
Frostegard J
J Intern Med
. 2022 Aug;
293(1):48-62.
PMID: 35982610
The prognosis in systemic lupus erythematosus (SLE) has improved due to better treatment and care, but cardiovascular disease (CVD) still remains an important clinical problem, since the risk of CVD...
8.
Samal S, Panda P, Vikstrom M, Leander K, de Faire U, Ahuja R, et al.
Front Cardiovasc Med
. 2022 Apr;
9:809007.
PMID: 35479288
Aims: Antibodies against phosphorylcholine (anti-PC) are implicated as protection markers in atherosclerosis, cardiovascular disease (CVD), and other chronic inflammatory conditions. Mostly, these studies have been focused on IgM. In this...
9.
Frostegard J
Expert Rev Clin Immunol
. 2022 Apr;
18(5):525-532.
PMID: 35471137
Introduction: Chronic inflammatory diseases include cardiovascular disease (CVD), atherosclerosis, rheumatic and autoimmune diseases, and others, constituting a large part of the disease burden. It is therefore of major importance to...
10.
Frostegard J
Expert Rev Clin Immunol
. 2021 Dec;
18(1):67-74.
PMID: 34928185
Introduction: Statins have pleiotropic effects, being both anti-inflammatory and immunomodulatory. Proprotein convertase subtilisin kexin 9 (PCSK9) targets the low-density lipoprotein receptor (LDLR), which increases LDL levels due to the lower...